1887
Volume 2015, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

There is no abstract available for this article.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2015.13
2015-04-04
2019-08-18
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/1/gcsp.2015.13.html?itemId=/content/journals/10.5339/gcsp.2015.13&mimeType=html&fmt=ahah

References

  1. [1]. D'Alonzo   GE., , Barst   RJ., , Ayres   SM., , Bergofsky   EH., , Brundage   BH., , Detre   KM., , Fishman   AP., , Goldring   RM., , Groves   BM., , Kernis   JT., , Levy   PS., , Pietra   GG., , Reid   LM., , Reeves   JT., , Rich   S., , Vreim   CE., , Williams   GW., , Wu   M. . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. . Annals of Internal Medicine . 1991; ;115: 5 : 343– 349 .
    [Google Scholar]
  2. [2]. Rich   S., , Dantzker   DR., , Ayres   SM., , Bergofsky   EH., , Brundage   BH., , Detre   KM., , Fishman   AP., , Goldring   RM., , Groves   BM., , Koerner   SK. . Primary pulmonary hypertension. A national prospective study. . Annals of Internal Medicine . 1987; ;107: 2 : 216– 223 .
    [Google Scholar]
  3. [3]. McGoon   MD., , Benza   RL., , Escribano-Subias   P., , Jiang   X., , Miller   DP., , Peacock   AJ., , Pepke-Zaba   J., , Pulido   T., , Rich   S., , Rosenkranz   S., , Suissa   S., , Humbert   M. . Pulmonary arterial hypertension: epidemiology and registries. . Journal of the American College of Cardiology . 2013; ;62: 25, Supplement : D51– D59 .
    [Google Scholar]
  4. [4]. Benza   RL., , Miller   DP., , Barst   RJ., , Badesch   DB., , Frost   AE., , McGoon   MD. . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. . Chest . 2012; ;142: 2 : 448– 456 .
    [Google Scholar]
  5. [5]. Escribano-Subias   P., , Blanco   I., , López-Meseguer   M., , Lopez-Guarch   CJ., , Roman   A., , Morales   P., , Castillo-Palma   MJ., , Segovia   J., , Gómez-Sanchez   MA., , Barberà   JA. . Survival in pulmonary hypertension in Spain: insights from the Spanish registry. . European Respiratory Journal . 2012; ;40: 3 : 596– 603 .
    [Google Scholar]
  6. [6]. Humbert   M., , Sitbon   O., , Yaïci   A., , Montani   D., , O'Callaghan   DS., , Jaïs   X., , Parent   F., , Savale   L., , Natali   D., , Günther   S., , Chaouat   A., , Chabot   F., , Cordier   J-F., , Habib   G., , Gressin   V., , Jing   ZC., , Souza   R., , Simonneau   G. . French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. . European Respiratory Journal . 2010; ;36: 3 : 549– 555 .
    [Google Scholar]
  7. [7]. Humbert   M., , Sitbon   O., , Chaouat   A., , Bertocchi   M., , Habib   G., , Gressin   V., , Yaïci   A., , Weitzenblum   E., , Cordier   J-F., , Chabot   F., , Dromer   C., , Pison   C., , Reynaud-Gaubert   M., , Haloun   A., , Laurent   M., , Hachulla   E., , Cottin   V., , Degano   B., , Jaïs   X., , Montani   D., , Souza   R. . Survival in patients With idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. . Circulation . 2010; ;122: 2 : 156– 163 .
    [Google Scholar]
  8. [8]. Ling   Y., , Johnson   MK., , Kiely   DG., , Condliffe   R., , Elliot   CA., , Gibbs   JSR., , Howard   LS., , Pepke-Zaba   J., , Sheares   KKK., , Corris   PA., , Fisher   AJ., , Lordan   JL., , Gaine   S., , Coghlan   JG., , Wort   SJ., , Gatzoulis   MA., , Peacock   AJ. . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension. . American Journal of Respiratory and Critical Care Medicine . 2012; ;186: 8 : 790– 796 .
    [Google Scholar]
  9. [9]. Zaiman   A., , Fijalkowska   I., , Hassoun   PM., , Tuder   RM. . One hundred years of research in the pathogenesis of pulmonary hypertension. . American Journal of Respiratory Cell and Molecular Biology . 2005; ;33: 5 : 425– 431 .
    [Google Scholar]
  10. [10]. ElMaghawry   M., , Zanatta   A., , Zampieri   F. . The discovery of pulmonary circulation: From Imhotep to William Harvey. . Global Cardiology Science and Practice . 2014; ;2014: 2 : 31 .
    [Google Scholar]
  11. [11]. West   JB. . Ibn al-Nafis, the pulmonary circulation, and the Islamic Golden Age. . Journal of Applied Physiology . 2008; ;105: 6 : 1877– 1880 .
    [Google Scholar]
  12. [12]. Klob , Wien Wochenbl . 1865; ;31: : 45 .
    [Google Scholar]
  13. [13]. Van Wolferen   SA., , Grünberg   K., , Vonk Noordegraaf   A. . Diagnosis and management of pulmonary hypertension over the past 100 years. . Respiratory Medicine . 2007; ;101: 3 : 389– 398 .
    [Google Scholar]
  14. [14]. Von Romberg   E. . Uber sklerose der lungen arterie. . Dtsch Arch Klin Med . 1891; ;48: : 197– 206 .
    [Google Scholar]
  15. [15]. Mazzei   JA., , Mazzei   ME. . A tribute: Abel Ayerza and pulmonary hypertension. . European Respiratory Review . 2011; ;20: 122 : 220– 221 .
    [Google Scholar]
  16. [16]. Arrillaga . Sclerose de l'artere pulmonaire secondaire à certeins ètats pulmonaire chronique (Cardiaques Noirs). . Arch Mal Coeur . 1913; ;6: : 518– 529 .
    [Google Scholar]
  17. [17]. Brenner   OO. . Pathology of the vessels of the pulmonary circulation: Part I. . Archives of Internal Medicine . 1935; ;56: 2 : 211– 237 .
    [Google Scholar]
  18. [18]. Fishman   AP. . Primary pulmonary arterial hypertension: A look back. . Journal of the American College of Cardiology . 2004; ;43: 12, Supplement : S2– S4 .
    [Google Scholar]
  19. [19]. Forssmann   DW. . Die Sondierung des Rechten Herzens. . Klinische Wochenschrift . 1929; ;8: 45 : 2085– 2087 .
    [Google Scholar]
  20. [20]. Cournand   A., , Ranges   HA. . Catheterization of the right auricle in man. . Experimental Biology and Medicine . 1941; ;46: 3 : 462– 466 .
    [Google Scholar]
  21. [21]. Cournand   A. . Pulmonary circulation: Its control in man, with some remarks on methodology. . Science . 1957; ;125: 3260 : 1231– 1235 .
    [Google Scholar]
  22. [22]. Cournand   A., , Riley   RL., , Breed   ES., , Baldwin   ED., , Richards   DW., , Lester   MS., , Jones   M. . Measurement of cardiac output in man using the technique of catherization of the right auricle of ventricle. . Journal of Clinical Investigation . 1945; ;24: 1 : 106– 116 .
    [Google Scholar]
  23. [23]. Richards   DW. . Right heart catheterization its contributions to physiology and medicine. . Science . 1957; ;125: 3259 : 1181– 1185 .
    [Google Scholar]
  24. [24]. Dresdale   DT., , Schultz   M., , Michtom   RJ. . Primary pulmonary hypertension: I. Clinical and hemodynamic study. . The American Journal of Medicine . 1951; ;11: 6 : 686– 705 .
    [Google Scholar]
  25. [25]. Wood   P. . Pulmonary hypertension. . British Medical Bulletin . 1952; ;8: 4 : 348– 353 .
    [Google Scholar]
  26. [26]. Dresdale   DT., , Michtom   RJ., , Schultz   M. . Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance. . Bulletin of the New York Academy of Medicine . 1954; ;30: 3 : 195– 207 .
    [Google Scholar]
  27. [27]. Harris   P. . Influence of acetylcholine on the pulmonary arterial pressure. . British Heart Journal . 1957; ;19: 2 : 272– 278 .
    [Google Scholar]
  28. [28]. Hatano   S., , Strasser   T. . Primary pulmonary hypertension: Report on a WHO meeting Geneva 15-17 October 1973 . World Health Organisation;   1975; .
    [Google Scholar]
  29. [29]. Gurtner   HP., , Gertsch   M., , Salzmann   C., , Scherrer   M., , Stucki   P., , Wyss   F. . [Are the primary vascular forms of chronic pulmonary heart disease becoming more common?]. . Schweizerische Medizinische Wochenschrift . 1968; ;98: 41 : 1579– 1589 .
    [Google Scholar]
  30. [30]. Gurtner   HP. . Aminorex and pulmonary hypertension. . Cor Et Vasa . 1985; ;27: 2 : 160– 171 .
    [Google Scholar]
  31. [31]. Reitz   BA., , Wallwork   JL., , Hunt   SA., , Pennock   JL., , Billingham   ME., , Oyer   PE., , Stinson   EB., , Shumway   NE. . Heart-lung transplantation: Successful therapy of patients with pulmonary vascular disease. . New England Journal of Medicine . 1982; ;306: 10 : 557– 564 .
    [Google Scholar]
  32. [32]. Rich   S., , Brundage   BH. . High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. . Circulation . 1987; ;76: 1 : 135– 141 .
    [Google Scholar]
  33. [33]. Rich   S., , Kaufmann   E., , Levy   PS. . The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. . New England Journal of Medicine . 1992; ;327: 2 : 76– 81 .
    [Google Scholar]
  34. [34]. Frank   H., , Mlczoch   J., , Huber   K., , Schuster   E., , Gurtner   HP., , Kneussl   M. . The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. . Chest . 1997; ;112: 3 : 714– 721 .
    [Google Scholar]
  35. [35]. Fuster   V., , Steele   PM., , Edwards   WD., , Gersh   BJ., , McGoon   MD., , Frye   RL. . Primary pulmonary hypertension: Natural history and the importance of thrombosis. . Circulation . 1984; ;70: 4 : 580– 587 .
    [Google Scholar]
  36. [36]. Olsson   KM., , Delcroix   M., , Ghofrani   HA., , Tiede   H., , Huscher   D., , Speich   R., , Grünig   E., , Staehler   G., , Rosenkranz   S., , Halank   M., , Held   M., , Lange   TJ., , Behr   J., , Klose   H., , Claussen   M., , Ewert   R., , Opitz   CF., , Vizza   CD., , Scelsi   L., , Vonk-Noordegraaf   A., , Kaemmerer   H. . Anticoagulation and survival in pulmonary arterial hypertension results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). . Circulation . 2014; ;129: 1 : 57– 65 .
    [Google Scholar]
  37. [37]. Moncada   S., , Gryglewski   R., , Bunting   S., , Vane   JR. . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. . Nature . 1976; ;263: 5579 : 663– 665 .
    [Google Scholar]
  38. [38]. Hyman   AL., , Chapnick   BM., , Kadowitz   PJ., , Lands   WE., , Crawford   CG., , Fried   J., , Barton   J. . Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with endoperoxides and other prostanoids. . Proceedings of the National Academy of Sciences of the United States of America . 1977; ;74: 12 : 5711– 5715 .
    [Google Scholar]
  39. [39]. Rubin   LJ., , Groves   BM., , Reeves   JT., , Frosolono   M., , Handel   F., , Cato   AE. . Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. . Circulation . 1982; ;66: 2 : 334– 338 .
    [Google Scholar]
  40. [40]. Higenbottam   T., , Wheeldon   D., , Wells   F., , Wallwork   J. . Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). . Lancet . 1984; ;1: 8385 : 1046– 1047 .
    [Google Scholar]
  41. [41]. Rubin   LJ., , Mendoza   J., , Hood   M., , McGoon   M., , Barst   R., , Williams   WB., , Diehl   JH., , Crow   J., , Long   W. . Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. . Annals of Internal Medicine . 1990; ;112: 7 : 485– 491 .
    [Google Scholar]
  42. [42]. Barst   RJ., , Rubin   LJ., , Long   WA., , McGoon   MD., , Rich   S., , Badesch   DB., , Groves   BM., , Tapson   VF., , Bourge   RC., , Brundage   BH., , Koerner   SK., , Langleben   D., , Keller   CA., , Murali   S., , Uretsky   BF., , Clayton   LM., , Jöbsis   MM., , Blackburn   SD., , Shortino   D., , Crow   JW. . Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. . New England Journal of Medicine . 1996; ;334: 5 : 296– 301 .
    [Google Scholar]
  43. [43]. Rich   S. . Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998 . World Health Organisation;   1998; .
    [Google Scholar]
  44. [44]. Simonneau   G., , Barst   R., , Galiè   N., , Naeije   R., , Rich   S., , Bourge   RC., , Keogh   AM., , Oudiz   RJ., , Frost   AE., , Blackburn   SD., , Crow   JW., , Rubin   LJ. . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients withpulmonary arterial hypertension. . American Journal of Respiratory and Critical Care Medicine . 2002; ;165: 6 : 800– 804 .
    [Google Scholar]
  45. [45]. Hoeper   MM., , Schwarze   M., , Ehlerding   S., , Adler-Schuermeyer   A., , Spiekerkoetter   E., , Niedermeyer   J., , Hamm   M., , Fabel   H. . Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. . New England Journal of Medicine . 2000; ;342: 25 : 1866– 1870 .
    [Google Scholar]
  46. [46]. Olschewski   H., , Simonneau   G., , Galiè   N., , Higenbottam   T., , Naeije   R., , Rubin   LJ., , Nikkho   S., , Speich   R., , Hoeper   MM., , Behr   J., , Winkler   J., , Sitbon   O., , Popov   W., , Ghofrani   HA., , Manes   A., , Kiely   DG., , Ewert   R., , Meyer   A., , Corris   PA., , Delcroix   M., , Gomez-Sanchez   M. . Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. . New England Journal of Medicine . 2002; ;347: 5 : 322– 329 .
    [Google Scholar]
  47. [47]. Channick   RN., , Simonneau   G., , Sitbon   O., , Robbins   IM., , Frost   A., , Tapson   VF., , Badesch   DB., , Roux   S., , Rainisio   M., , Bodin   F., , Rubin   LJ. . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. . The Lancet . 2001; ;358: 9288 : 1119– 1123 .
    [Google Scholar]
  48. [48]. Chester   AH., , Yacoub   MH. . The role of endothelin-1 in pulmonary arterial hypertension. . Global Cardiology Science and Practice . 2014; ;2014: 2 : 29 .
    [Google Scholar]
  49. [49]. Rubin   LJ., , Badesch   DB., , Barst   RJ., , Galiè   N., , Black   CM., , Keogh   A., , Pulido   T., , Frost   A., , Roux   S., , Leconte   I., , Landzberg   M., , Simonneau   G. . Bosentan therapy for pulmonary arterial hypertension. . New England Journal of Medicine . 2002; ;346: 12 : 896– 903 .
    [Google Scholar]
  50. [50]. Atz   AM., , Wessel   DL. . Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. . Anesthesiology . 1999; ;91: 1 : 307– 310 .
    [Google Scholar]
  51. [51]. Michelakis   E., , Tymchak   W., , Lien   D., , Webster   L., , Hashimoto   K., , Archer   S. . Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension comparison with inhaled nitric oxide. . Circulation . 2002; ;105: 20 : 2398– 2403 .
    [Google Scholar]
  52. [52]. Prasad   S., , Wilkinson   J., , Gatzoulis   MA. . Sildenafil in primary pulmonary hypertension. . New England Journal of Medicine . 2000; ;343: 18 : 1342– 1342 .
    [Google Scholar]
  53. [53]. Sastry   BKS., , Narasimhan   C., , Reddy   NK., , Raju   BS. . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. . Journal of the American College of Cardiology . 2004; ;43: 7 : 1149– 1153 .
    [Google Scholar]
  54. [54]. Simonneau   G., , Galiè   N., , Rubin   LJ., , Langleben   D., , Seeger   W., , Domenighetti   G., , Gibbs   S., , Lebrec   D., , Speich   R., , Beghetti   M., , Rich   S., , Fishman   A. . Clinical classification of pulmonary hypertension. . Journal of the American College of Cardiology . 2004; ;43: 12, Supplement : S5– S12 .
    [Google Scholar]
  55. [55]. Galiè   N., , Seeger   W., , Naeije   R., , Simonneau   G., , Rubin   LJ. . Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. . Journal of the American College of Cardiology . 2004; ;43: 12, Supplement : S81– S88 .
    [Google Scholar]
  56. [56]. Galiè   N., , Ghofrani   HA., , Torbicki   A., , Barst   RJ., , Rubin   LJ., , Badesch   D., , Fleming   T., , Parpia   T., , Burgess   G., , Branzi   A., , Grimminger   F., , Kurzyna   M., , Simonneau   G. . Sildenafil citrate therapy for pulmonary arterial hypertension. . New England Journal of Medicine . 2005; ;353: 20 : 2148– 2157 .
    [Google Scholar]
  57. [57]. Humbert   M., , McLaughlin   VV. . The 4th world symposium on pulmonary hypertension. . Journal of the American College of Cardiology . 2009; ;54: 1, Supplement : S1– S2 .
    [Google Scholar]
  58. [58]. Barst   RJ., , Gibbs   JSR., , Ghofrani   HA., , Hoeper   MM., , McLaughlin   VV., , Rubin   LJ., , Sitbon   O., , Tapson   VF., , Galiè   N. . Updated evidence-based treatment algorithm in pulmonary arterial hypertension. . Journal of the American College of Cardiology . 2009; ;54: 1, Supplement : S78– S84 .
    [Google Scholar]
  59. [59]. McLaughlin   VV., , Badesch   DB., , Delcroix   M., , Fleming   TR., , Gaine   SP., , Galiè   N., , Gibbs   JSR., , Kim   NH., , Oudiz   RJ., , Peacock   A., , Provencher   S., , Sitbon   O., , Tapson   VF., , Seeger   W. . End points and clinical trial design in pulmonary arterial hypertension. . Journal of the American College of Cardiology . 2009; ;54: 1, Supplement : S97– S107 .
    [Google Scholar]
  60. [60]. Pulido   T., , Adzerikho   I., , Channick   RN., , Delcroix   M., , Galiè   N., , Ghofrani   H-A., , Jansa   P., , Jing   Z-C., , Le Brun   F-O., , Mehta   S., , Mittelholzer   CM., , Perchenet   L., , Sastry   BKS., , Sitbon   O., , Souza   R., , Torbicki   A., , Zeng   X., , Rubin   LJ., , Simonneau   G., , SERAPHIN Investigators. . SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. . New England Journal of Medicine . 2013; ;369: 9 : 809– 818 .
    [Google Scholar]
  61. [61]. Ghofrani   H-A., , Galiè   N., , Grimminger   F., , Grünig   E., , Humbert   M., , Jing   Z-C., , Keogh   AM., , Langleben   D., , Kilama   MO., , Fritsch   A., , Neuser   D., , Rubin   LJ. . Riociguat for the treatment of pulmonary arterial hypertension. . New England Journal of Medicine . 2013; ;369: 4 : 330– 340 .
    [Google Scholar]
  62. [62]. Ghofrani   H-A., , D'Armini   AM., , Grimminger   F., , Hoeper   MM., , Jansa   P., , Kim   NH., , Mayer   E., , Simonneau   G., , Wilkins   MR., , Fritsch   A., , Neuser   D., , Weimann   G., , Wang   C. . Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. . New England Journal of Medicine . 2013; ;369: 4 : 319– 329 .
    [Google Scholar]
  63. [63]. Galiè   N., , Corris   PA., , Frost   A., , Girgis   RE., , Granton   J., , Jing   ZC., , Klepetko   W., , McGoon   MD., , McLaughlin   VV., , Preston   IR., , Rubin   LJ., , Sandoval   J., , Seeger   W., , Keogh   A. . Updated treatment algorithm of pulmonary arterial hypertension. . Journal of the American College of Cardiology . 2013; ;62: 25, Supplement : D60– D72 .
    [Google Scholar]
  64. [64]. Tuder   RM., , Archer   SL., , Dorfmüller   P., , Erzurum   SC., , Guignabert   C., , Michelakis   E., , Rabinovitch   M., , Schermuly   R., , Stenmark   KR., , Morrell   NW. . Relevant issues in the pathology and pathobiology of pulmonary hypertension. . Journal of the American College of Cardiology . 2013; ;62: 25, Supplement : D4– D12 .
    [Google Scholar]
  65. [65]. GlaxoSmithKline . A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION)..   2014; ; . http://clinicaltrials.gov/show/NCT01178073 .
    [Google Scholar]
  66. [66]. Simonneau   G., , Torbicki   A., , Hoeper   MM., , Delcroix   M., , Karlócai   K., , Galiè   N., , Degano   B., , Bonderman   D., , Kurzyna   M., , Efficace   M., , Giorgino   R., , Lang   IM. . Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. . The European Respiratory Journal . 2012; ;40: 4 : 874– 880 .
    [Google Scholar]
  67. [67]. Actelion . Selexipag (ACT-293987) in pulmonary arterial hypertension, GRIPHON Trial. . 2014; ; , http://clinicaltrials.gov/ct2/show/NCT01106014 .
    [Google Scholar]
  68. [68]. Actelion. Selexipag . 2014; ; . http://www1.actelion.co.uk/sites/en/scientists/development–pipeline/phase–3/selexipag.page (accessed 27 September 2014) .
  69. [69]. Wilkins   MR., , Ali   O., , Bradlow   W., , Wharton   J., , Taegtmeyer   A., , Rhodes   CJ., , Ghofrani   HA., , Howard   L., , Nihoyannopoulos   P., , Mohiaddin   RH., , Gibbs   JSR. . Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group. Simvastatin as a treatment for pulmonary hypertension trial. . American Journal of Respiratory and Critical Care Medicine . 2010; ;181: 10 : 1106– 1113 .
    [Google Scholar]
  70. [70]. Fukumoto   Y., , Matoba   T., , Ito   A., , Tanaka   H., , Kishi   T., , Hayashidani   S., , Abe   K., , Takeshita   A., , Shimokawa   H. . Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. . Heart . 2005; ;91: 3 : 391– 392 .
    [Google Scholar]
  71. [71]. Fukumoto   Y., , Yamada   N., , Matsubara   H., , Mizoguchi   M., , Uchino   K., , Yao   A., , Kihara   Y., , Kawano   M., , Watanabe   H., , Takeda   Y., , Adachi   T., , Osanai   S., , Tanabe   N., , Inoue   T., , Kubo   A., , Ota   Y., , Fukuda   K., , Nakano   T., , Shimokawa   H. . Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. . Circulation Journal: Official Journal of the Japanese Circulation Society . 2013; ;77: 10 : 2619– 2625 .
    [Google Scholar]
  72. [72]. Loyd   JE., , Primm   RK., , Newman   JH. . Familial primary pulmonary hypertension: Clinical patterns. . The American Review of Respiratory Disease . 1984; ;129: 1 : 194– 197 .
    [Google Scholar]
  73. [73]. Deng   Z., , Morse   JH., , Slager   SL., , Cuervo   N., , Moore   KJ., , Venetos   G., , Kalachikov   S., , Cayanis   E., , Fischer   SG., , Barst   RJ., , Hodge   SE., , Knowles   JA. . Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor–II gene. . The American Journal of Human Genetics . 2000; ;67: 3 : 737– 744 .
    [Google Scholar]
  74. [74]. Lane   KB., , Machado   RD., , Pauciulo   MW., , Thomson   JR., , Phillips   JA., , Loyd   JE., , Nichols   WC., , Trembath   RC. . Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. . Nature Genetics . 2000; ;26: 1 : 81– 84 .
    [Google Scholar]
  75. [75]. Soubrier   F., , Chung   WK., , Machado   R., , Grünig   E., , Aldred   M., , Geraci   M., , Loyd   JE., , Elliott   CG., , Trembath   RC., , Newman   JH., , Humbert   M. . Genetics and genomics of pulmonary arterial hypertension. . Journal of the American College of Cardiology . 2013; ;62: 25, Supplement : D13– D21 .
    [Google Scholar]
  76. [76]. Upton   PD., , Morrell   NW. . The transforming growth factor-β–bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. . Experimental Physiology . 2013; ;98: 8 : 1262– 1266 .
    [Google Scholar]
  77. [77]. Machado   RD., , Eickelberg   O., , Elliott   CG., , Geraci   MW., , Hanaoka   M., , Loyd   JE., , Newman   JH., , Phillips   SoubrierF III JA., , Trembath   RC., , Chung   WK. . Genetics and genomics of pulmonary arterial hypertension. . Journal of the American College of Cardiology . 2009; ;54: 1, Supplement : S32– S42 .
    [Google Scholar]
  78. [78]. Rabinovitch   M., , Guignabert   C., , Humbert   M., , Nicolls   MR. . Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. . Circulation Research . 2014; ;115: 1 : 165– 175 .
    [Google Scholar]
  79. [79]. Saco   TV., , Parthasarathy   PT., , Cho   Y., , Lockey   RF., , Kolliputi   N. . Role of epigenetics in pulmonary hypertension. . American Journal of Physiology - Cell Physiology . 2014; ;306: 12 : C1101– C1105 .
    [Google Scholar]
  80. [80]. Paulin   R., , Michelakis   ED. . The metabolic theory of pulmonary arterial hypertension. . Circulation Research . 2014; ;115: 1 : 148– 164 .
    [Google Scholar]
  81. [81]. Hoeper   MM., , Barst   RJ., , Bourge   RC., , Feldman   J., , Frost   AE., , Galié   N., , Gómez-Sánchez   MA., , Grimminger   F., , Grünig   E., , Hassoun   PM., , Morrell   NW., , Peacock   AJ., , Satoh   T., , Simonneau   G., , Tapson   VF., , Torres   F., , Lawrence   D., , Quinn   DA., , Ghofrani   HA. . Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. . Circulation . 2013; ;127: 10 : 1128– 1138 .
    [Google Scholar]
  82. [82]. Godinas   L., , Guignabert   C., , Seferian   A., , Perros   F., , Bergot   E., , Sibille   Y., , Humbert   M., , Montani   D. . Tyrosine kinase inhibitors in pulmonary arterial hypertension: A double-edge sword?.   Seminars in Respiratory and Critical Care Medicine . 2013; ;34: 5 : 714– 724 .
    [Google Scholar]
  83. [83]. Novartis . Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). . 2014; ; . http://clinicaltrials.gov/ct2/show/results/NCT01179737 .
    [Google Scholar]
  84. [84]. Spiekerkoetter   E. . FK506 (tacrolimus) in pulmonary arterial hypertension (TransformPAH). . 2012; ; . http://clinicaltrials.gov/show/NCT01647945 .
    [Google Scholar]
  85. [85]. Michelakis   E., , Wilkins   MR. . Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension. . 2014; ; . http://clinicaltrials.gov/show/NCT01083524 .
    [Google Scholar]
  86. [86]. Taniguchi   K., , Shimazaki   C., , Fujimoto   Y., , Shimura   K., , Uchiyama   H., , Matsumoto   Y., , Kuroda   J., , Horiike   S., , Taniwaki   M. . Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. . International Journal of Hematology . 2009; ;90: 1 : 99– 102 .
    [Google Scholar]
  87. [87]. Furuya   Y., , Satoh   T., , Kuwana   M. . Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. . International Journal of Rheumatology . 2010; ;2010: : 720305 .
    [Google Scholar]
  88. [88]. Kadavath   S., , Zapantis   E., , Zolty   R., , Efthimiou   P. . A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: Targeting IL-6. . International Journal of Rheumatic Diseases . 2014; ;17: 3 : 336– 340 .
    [Google Scholar]
  89. [89]. Ohira   H., , Beanlands   RS., , Davies   RA., , Mielniczuk   L. . The role of nuclear imaging in pulmonary hypertension. . Journal of Nuclear Cardiology . 2014; ; 1– 17 .
    [Google Scholar]
  90. [90]. Reynolds   AM., , Holmes   MD., , Danilov   SM., , Reynolds   PN. . Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. . European Respiratory Journal . 2012; ;39: 2 : 329– 343 .
    [Google Scholar]
  91. [91]. Ramsey   BW., , Davies   J., , McElvaney   NG., , Tullis   E., , Bell   SC., , Devínek   P., , Griese   M., , McKone   EF., , Wainwright   CE., , Konstan   MW., , Moss   R., , Ratjen   F., , Sermet-Gaudelus   I., , Rowe   SM., , Dong   Q., , Rodriguez   S., , Yen   K., , Ordoñez   C., , Elborn   JS. . VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. . New England Journal of Medicine . 2011; ;365: 18 : 1663– 1672 .
    [Google Scholar]
  92. [92]. Montani   D., , Chaumais   M-C., , Guignabert   C., , Günther   S., , Girerd   B., , Jaïs   X., , Algalarrondo   V., , Price   LC., , Savale   L., , Sitbon   O., , Simonneau   G., , Humbert   M. . Targeted therapies in pulmonary arterial hypertension. . Pharmacology & Therapeutics.   2014; ;141: 2 : 172– 191 .
    [Google Scholar]
  93. [93]. Simonneau   G., , Gatzoulis   MA., , Adatia   I., , Celermajer   D., , Denton   C., , Ghofrani   A., , Gomez Sanchez   MA., , Krishna Kumar   R., , Landzberg   M., , Machado   RF., , Olschewski   H., , Robbins   IM., , Souza   R. . Updated Clinical Classification of Pulmonary Hypertension. . Journal of the American College of Cardiology . 2013; ;62: 25_S .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.13
Loading
/content/journals/10.5339/gcsp.2015.13
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error